These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1762644)

  • 21. Views of Australian mental health stakeholders on clients' problematic drug and alcohol use.
    Cleary M; Hunt GE; Matheson S; Walter G
    Drug Alcohol Rev; 2009 Mar; 28(2):122-8. PubMed ID: 19320696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I: status report of existing data on the effectiveness, cost, and cost effectiveness of nutrition care services.
    Splett PL
    J Am Diet Assoc; 1991 Nov; Suppl():S9-14. PubMed ID: 1834722
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic costs, cost-effectiveness, financing, and community-based drug treatment.
    NIDA Res Monogr; 1991; 113():1-211. PubMed ID: 1762633
    [No Abstract]   [Full Text] [Related]  

  • 24. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
    Fleming E; Lien H; Ma CT; McGuire TG
    J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does treatment 'pay for itself'? Looking at the economic argument for addiction treatment.
    Ettner SL
    Behav Healthc; 2006 May; 26(5):32-4. PubMed ID: 16736917
    [No Abstract]   [Full Text] [Related]  

  • 26. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome measurement issues in drug abuse prevention studies.
    Dwyer JH; MacKinnon DP
    NIDA Res Monogr; 1991; 107():183-94. PubMed ID: 1922305
    [No Abstract]   [Full Text] [Related]  

  • 28. Performance of statistical models to predict mental health and substance abuse cost.
    Montez-Rath M; Christiansen CL; Ettner SL; Loveland S; Rosen AK
    BMC Med Res Methodol; 2006 Oct; 6():53. PubMed ID: 17067394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of alcohol and drug treatment programs.
    Caldwel JR
    J Fla Med Assoc; 1993 Jun; 80(6):385-6. PubMed ID: 8340771
    [No Abstract]   [Full Text] [Related]  

  • 30. Unmet substance abuse treatment need, health services utilization, and cost: a population-based emergency department study.
    Rockett IR; Putnam SL; Jia H; Chang CF; Smith GS
    Ann Emerg Med; 2005 Feb; 45(2):118-27. PubMed ID: 15671966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interpretation of quality-of-life outcomes: issues that affect magnitude and meaning.
    Testa MA
    Med Care; 2000 Sep; 38(9 Suppl):II166-74. PubMed ID: 10982103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of health economics in substance abuse research. Recent advances and future opportunities. Overview.
    French MT
    Recent Dev Alcohol; 2001; 15():201-8. PubMed ID: 11449742
    [No Abstract]   [Full Text] [Related]  

  • 33. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Policy-relevant research on drug treatment.
    Gerstein DR
    NIDA Res Monogr; 1991; 113():129-47. PubMed ID: 1762636
    [No Abstract]   [Full Text] [Related]  

  • 35. The epidemiology of drug abuse: current issues. Surveys--longitudinal studies.
    Johnston LD
    NIDA Res Monogr; 1977 Mar; (10):60-7. PubMed ID: 405612
    [No Abstract]   [Full Text] [Related]  

  • 36. Seven reasons why you should not categorize continuous data.
    Dinero TE
    J Health Soc Policy; 1996; 8(1):63-72. PubMed ID: 10162905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Chief Scientist reports.... Problems in mounting and maintaining longitudinal studies--examples from dental health services research.
    Davies JA; Fyffe HE; Pitts NB
    Health Bull (Edinb); 1992 Mar; 50(2):194-205. PubMed ID: 1517092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selected methodological issues in evaluating community-based health promotion and disease prevention programs.
    Koepsell TD; Wagner EH; Cheadle AC; Patrick DL; Martin DC; Diehr PH; Perrin EB; Kristal AR; Allan-Andrilla CH; Dey LJ
    Annu Rev Public Health; 1992; 13():31-57. PubMed ID: 1599591
    [No Abstract]   [Full Text] [Related]  

  • 39. [Expenditure and success in the treatment of drug addicts].
    Arnold H
    MMW Munch Med Wochenschr; 1977 Sep; 119(38):1201. PubMed ID: 409940
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-benefit and cost-effectiveness analysis of drug abuse treatment services.
    Cartwright WS
    Eval Rev; 1998 Oct; 22(5):609-36. PubMed ID: 10186896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.